Vinge has advised Veeco Instruments Inc. ("Veeco"), a US company listed on NASDAQ, in its acquisition of Epiluvac AB, a privately held manufacturer of chemical vapor deposition epitaxy systems that enable advanced silicon carbide (“SiC”) applications in the electric vehicle market. Epiluvac, based in Lund, Sweden, was founded in 2013 by a highly experienced team in SiC.

Epiluvac’s technology platform combined with Veeco’s global go-to-market capabilities is expected to create a significant long-term growth driver for Veeco. Epiluvac is an early-stage revenue company with 11 employees. The purchase price for the transaction, all payable in cash, is $30 million paid at the time of closing with a potential additional $35 million in performance based earn-outs.

Vinge's team consisted of, among others, Jonas Bergström, Carl Sander, Stina Bengtsson and Robin Sultani (M&A), Sofia Bergenstråhle and Arvid Axelryd (IP), Anna Ståhlklo and Jonna Skog (Employment), Victor Ericsson and Emelie Svanberg (Tax), Nicklas Thorgerzon (IT & GDPR) and Jasmina Skandrani (Project Assistant).

 

Related

Vinge has advised Oncopeptides in connection with a directed share issue

Vinge has advised Oncopeptides in connection with a directed share issue, whereby Oncopeptides raises proceeds of SEK 100 million.
October 16, 2026

Vinge advises KGAL on its divestment of a Nordic wind portfolio to Enordic Evergreen

Vinge has advised KGAL on the divestment of a Nordic onshore wind portfolio to Enordic Evergreen.
October 14, 2026

Vinge has advised Orexo in connection with its rights issue

Vinge has advised Orexo AB (publ) in connection with a partially guaranteed rights issue of approximately SEK 250 million before transaction costs, subject to approval by an extraordinary general meeting.
October 09, 2026